Foghorn sinks plans for eye tumor drug after glimpsing phase 1 data

Foghorn Therapeutics isn’t having much luck with FHD-286. Only weeks after the FDA released a trial of the drug in two blood cancers from a clinical hold, the biotech has abandoned plans for the candidate in an eye tumor after taking a look at phase 1 data.